Immunosuppression in Liver Transplantation: Renoprotective Regimens

被引:3
|
作者
Serrano Aullo, M. Trinidad [1 ]
Parra Moncasi, Eduardo [2 ]
Lorente Perez, Sara [1 ]
机构
[1] Hosp Clin Univ Lozano Blesa, Serv Digest, Unidad Trasplante Hepat, Zaragoza, Spain
[2] Hosp Reina Sofia, Serv Nefrol, Tudela, Spain
来源
GASTROENTEROLOGIA Y HEPATOLOGIA | 2011年 / 34卷 / 06期
关键词
Immunosuppression; Renal insufficiency; Liver transplantation; CHRONIC RENAL DYSFUNCTION; MYCOPHENOLATE-MOFETIL; CALCINEURIN INHIBITORS; INDUCTION THERAPY; DOSE TACROLIMUS; RECIPIENTS; SIROLIMUS; CYCLOSPORINE; CONVERSION; MONOTHERAPY;
D O I
10.1016/j.gastrohep.2010.12.009
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Both acute and chronic renal insufficiency are highly prevalent in liver transplant recipients. The etiology is multifactorial, with administration of nephrotoxic drugs playing a major role. Calcineurin inhibitors (CNI) (cyclosporin and tacrolimus) are the mainstay of immunosuppressive therapy in liver transplantation and produce acute and chronic nephrotoxicity. There are three main strategies to prevent renal injury: a) reduction of CNI to minimal levels accompanied by the use of an adjuvant drug such as azathioprine, mycophenolate mofetil or mammalian target of rapamycin (mTOR) inhibitors; b) complete withdrawal of CNI, using non-nephrotoxic drugs in their place; and c) use of protocols without CNI from the outset. The present article reviews these three strategies as well as their influence on renal function and on the results of liver transplantation. (C) 2010 Elsevier Espana, S.L. All rights reserved.
引用
收藏
页码:422 / 427
页数:6
相关论文
共 50 条
  • [31] Update: Immunosuppression during Organ Transplantation
    Kniepeiss, Daniela
    Rosenkranz, Alexander R.
    Fickert, Peter
    Schemmer, Peter
    TRANSFUSIONSMEDIZIN, 2020, 10 (04) : 221 - 231
  • [32] Review on immunosuppression in liver transplantation
    Moini, Maryam
    Schilsky, Michael L.
    Tichy, Eric M.
    WORLD JOURNAL OF HEPATOLOGY, 2015, 7 (10) : 1355 - 1368
  • [33] Review on immunosuppression in liver transplantation
    Maryam Moini
    Michael L Schilsky
    Eric M Tichy
    World Journal of Hepatology, 2015, (10) : 1355 - 1368
  • [34] Management of Immunosuppression in Liver Transplantation
    Dhanasekaran, Renumathy
    CLINICS IN LIVER DISEASE, 2017, 21 (02) : 337 - +
  • [35] Efficacy and safety of basiliximab as initial immunosuppression in liver transplantation: A single center study
    Hashim, Mohamed
    Alsebaey, Ayman
    Ragab, Amr
    Soliman, Hossam Eldeen
    Waked, Imam
    ANNALS OF HEPATOLOGY, 2020, 19 (05) : 541 - 545
  • [36] Immunosuppression in Pediatric Liver Transplantation: Are Little People Different?
    Dhawan, Anil
    LIVER TRANSPLANTATION, 2011, 17 : S13 - S19
  • [37] Current Status of Immunosuppression in Liver Transplantation
    Choudhary, Narendra S.
    Saigal, Sanjiv
    Shuklay, Rajat
    Kotecha, Hardik
    Saraf, Neeraj
    Soin, Arvinder S.
    JOURNAL OF CLINICAL AND EXPERIMENTAL HEPATOLOGY, 2013, 3 (02) : 150 - 158
  • [38] Future Prospects in Immunosuppression for Liver Transplantation
    Fung, John J.
    Bollinger, Jessica E.
    Miller, Charles
    Eghtesad, Bijan
    LIVER TRANSPLANTATION, 2011, 17 : S54 - S59
  • [39] Induction immunosuppression in liver transplantation: a review
    Turner, Alexandra P.
    Knechtle, Stuart J.
    TRANSPLANT INTERNATIONAL, 2013, 26 (07) : 673 - 683
  • [40] Decreased effect of immunosuppression on immunocompetence in African-Americans after kidney and liver transplantation
    Nagashima, N
    Watanabe, T
    Nakamura, M
    Shalabi, A
    Burdick, JF
    CLINICAL TRANSPLANTATION, 2001, 15 (02) : 111 - 115